首页> 美国卫生研究院文献>International Journal of Womens Health >Potential role of aromatase inhibitors in the treatment of endometriosis
【2h】

Potential role of aromatase inhibitors in the treatment of endometriosis

机译:芳香化酶抑制剂在子宫内膜异位症治疗中的潜在作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Endometriosis is an estrogen-dependent chronic inflammatory disease affecting 5%–10% of reproductive-age women, with a prevalence of 5%–50% in infertile women and >33% of women with chronic pelvic pain. Third-generation aromatase inhibitors (AIs) are approved adjuvants for the treatment of estrogen receptor-positive breast cancer. Molecular studies have revealed the presence of aromatase P450, the key enzyme in the biosynthesis of ovarian estradiol, inside the endometriotic tissue, indicating local synthesis of estradiol. Thereby, AIs represent an appealing medical option for the management of different aspects of this enigmatic disease, especially pelvic pain and infertility. Accordingly, this review aims to evaluate the potential role of AIs in the treatment of endometriosis-associated symptoms, mainly pain and infertility. Notably, several studies have demonstrated that the combination of AIs with conventional therapy as oral contraceptive pills, progestins, or gonadotropin-releasing hormone analogs can be used to control endometriosis-associated pain and pain recurrence in premenopausal women, particularly those with pain due to rectovaginal endometriosis refractory to other medical or surgical treatment. Some case reports have shown promising results in the treatment of postmenopausal endometriosis as first-line treatment, when surgery is contraindicated, or as second-line treatment in the case of postoperative recurrence. Third-generation AIs, especially letrozole, have challenged clomiphene citrate as an ovulation-induction agent in patients with polycystic ovary syndrome and in cases of unexplained infertility. However, few studies are available regarding the use of AIs to treat endometriosis-associated infertility. Therefore, larger multicenter randomized trials using AIs for the treatment of endometriosis-associated infertility are needed to clarify its effect. The safety of AIs for ovulation induction or superovulation has generated a lively discussion. Data from recent retrospective and prospective studies have supported its safety.
机译:子宫内膜异位症是一种依赖雌激素的慢性炎症性疾病,影响了5%–10%的育龄妇女,其中不育妇女的患病率为5%–50%,慢性盆腔疼痛的患病率为33%。第三代芳香化酶抑制剂(AIs)被批准为治疗雌激素受体阳性乳腺癌的佐剂。分子研究表明,子宫内膜异位症组织内部存在着芳香酶P450,这是卵巢雌二醇生物合成中的关键酶,表明雌二醇是局部合成的。因此,人工授精是治疗这种神秘疾病不同方面,尤其是盆腔疼痛和不育症的一种有吸引力的医学选择。因此,本综述旨在评估AI在治疗子宫内膜异位相关症状(主要是疼痛和不孕症)中的潜在作用。值得注意的是,数项研究表明,将AI与口服避孕药,孕激素或促性腺激素释放激素类似物的常规疗法相结合,可用于控制子宫内膜异位症相关的疼痛和绝经前妇女的疼痛复发,尤其是那些因直肠阴道疼痛引起的疼痛其他医学或外科治疗难以治愈的子宫内膜异位症。一些病例报告显示在绝经后子宫内膜异位症的治疗中,当禁忌手术时作为一线治疗,或在术后复发时作为二线治疗,具有可喜的结果。在多囊卵巢综合征患者和无法解释的不育症患者中,第三代AI,尤其是来曲唑已经挑战了柠檬酸克罗米芬作为排卵诱导剂。但是,关于使用AI治疗子宫内膜异位症相关性不育的研究很少。因此,需要使用AIs治疗子宫内膜异位症相关不育症的大型多中心随机试验,以阐明其效果。人工授精诱导排卵或超排卵的安全性引起了热烈的讨论。最近的回顾性研究和前瞻性研究的数据支持了它的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号